N/A
Completed N=23
Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation
Dry Eye Syndromes
Source: ClinicalTrials.gov NCT02385292 ↗
Enrolled (actual)
23
Serious AEs
—
Results posted
Oct 2021
Primary outcomePrimary: Fluorescein Tear Clearance With Application
Summary
The objectives of this study are:
* To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications
* To compare the goblet cell count following application between the intranasal and extranasal applications
* To compare fluorescein tear clearance with the application of the device intranasally and extranasally applications
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fluorescein Tear Clearance With Application |
— | — |
Eligibility Criteria
Inclusion Criteria
- Bilateral dry eyes
- Capable of providing written informed consent
Exclusion Criteria
- Chronic or recurring epistaxis (nosebleeds)
- Blood coagulation disorder
- Uncontrolled or poorly controlled diabetes
- Heart or pulmonary disease
- Females who are pregnant, planning a pregnancy or nursing
Data sourced from ClinicalTrials.gov (NCT02385292). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.